Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.
Cancer genetic risk assessment
Early detection of cancer
Extended Parallel Process Model
Genetic counseling
Hereditary breast and ovarian cancer syndrome
Remote behavioral intervention
Journal
Annals of behavioral medicine : a publication of the Society of Behavioral Medicine
ISSN: 1532-4796
Titre abrégé: Ann Behav Med
Pays: England
ID NLM: 8510246
Informations de publication
Date de publication:
16 10 2023
16 10 2023
Historique:
pmc-release:
02
09
2024
medline:
23
10
2023
pubmed:
4
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
A theory-guided Tailored Counseling and Navigation (TCN) intervention successfully increased cancer genetic risk assessment (CGRA) uptake among cancer survivors at increased risk of hereditary breast and ovarian cancer (HBOC). Understanding the pathways by which interventions motivate behavior change is important for identifying the intervention's active components. We examined whether the TCN intervention exerted effects on CGRA uptake through hypothesized theoretical mediators. Cancer survivors at elevated risk for HBOC were recruited from three statewide cancer registries and were randomly assigned to three arms: TCN (n = 212), Targeted Print (TP, n = 216), and Usual Care (UC, n = 213). Theoretical mediators from the Extended Parallel Process Model, Health Action Planning Approach, and Ottawa Decision Support Framework were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. Generalized structural equation modeling was used for mediation analysis. The TCN effects were most strongly mediated by behavioral intention alone (β = 0.49 and 0.31) and by serial mediation through self-efficacy and intention (β = 0.041 and 0.10) when compared with UC and TP, respectively. In addition, compared with UC, the TCN also increased CGRA through increased perceived susceptibility, knowledge of HBOC, and response efficacy. Risk communication and behavioral change interventions for hereditary cancer should stress a person's increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove barriers to CGRA. System-level and policy interventions are needed to further expand access. It is recommended that cancer survivors at increased risk for heredity seek cancer genetic risk assessment (CGRA), which includes cancer genetic counseling and genetic testing. A Tailored Counseling and Navigation (TCN) intervention successfully increased CGRA uptake among women with a history of cancer who enrolled in a randomized controlled trial. Understanding reasons for TCN’s effectiveness can guide future interventions that use risk messages and behavior change techniques. We conducted mediation analyses, which enabled identification of the TCN’s active components. Eligible breast and ovarian cancer survivors (n = 641) were recruited from three statewide cancer registries and were assigned to three groups: TCN, Targeted Print, and Usual Care. Mediator variables drawn from behavioral and risk communication theories were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. The strongest mediator was intention to obtain a CGRA, followed by self-efficacy, perceived risk, knowledge of hereditary breast and ovarian cancer, and perceived CGRA benefits. Risk communication and behavioral change interventions for hereditary cancer should stress a person’s increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove CGRA barriers. System-level and policy interventions are needed to further expand access.
Sections du résumé
BACKGROUND
A theory-guided Tailored Counseling and Navigation (TCN) intervention successfully increased cancer genetic risk assessment (CGRA) uptake among cancer survivors at increased risk of hereditary breast and ovarian cancer (HBOC). Understanding the pathways by which interventions motivate behavior change is important for identifying the intervention's active components.
PURPOSE
We examined whether the TCN intervention exerted effects on CGRA uptake through hypothesized theoretical mediators.
METHODS
Cancer survivors at elevated risk for HBOC were recruited from three statewide cancer registries and were randomly assigned to three arms: TCN (n = 212), Targeted Print (TP, n = 216), and Usual Care (UC, n = 213). Theoretical mediators from the Extended Parallel Process Model, Health Action Planning Approach, and Ottawa Decision Support Framework were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. Generalized structural equation modeling was used for mediation analysis.
RESULTS
The TCN effects were most strongly mediated by behavioral intention alone (β = 0.49 and 0.31) and by serial mediation through self-efficacy and intention (β = 0.041 and 0.10) when compared with UC and TP, respectively. In addition, compared with UC, the TCN also increased CGRA through increased perceived susceptibility, knowledge of HBOC, and response efficacy.
CONCLUSIONS
Risk communication and behavioral change interventions for hereditary cancer should stress a person's increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove barriers to CGRA. System-level and policy interventions are needed to further expand access.
It is recommended that cancer survivors at increased risk for heredity seek cancer genetic risk assessment (CGRA), which includes cancer genetic counseling and genetic testing. A Tailored Counseling and Navigation (TCN) intervention successfully increased CGRA uptake among women with a history of cancer who enrolled in a randomized controlled trial. Understanding reasons for TCN’s effectiveness can guide future interventions that use risk messages and behavior change techniques. We conducted mediation analyses, which enabled identification of the TCN’s active components. Eligible breast and ovarian cancer survivors (n = 641) were recruited from three statewide cancer registries and were assigned to three groups: TCN, Targeted Print, and Usual Care. Mediator variables drawn from behavioral and risk communication theories were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. The strongest mediator was intention to obtain a CGRA, followed by self-efficacy, perceived risk, knowledge of hereditary breast and ovarian cancer, and perceived CGRA benefits. Risk communication and behavioral change interventions for hereditary cancer should stress a person’s increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove CGRA barriers. System-level and policy interventions are needed to further expand access.
Autres résumés
Type: plain-language-summary
(eng)
It is recommended that cancer survivors at increased risk for heredity seek cancer genetic risk assessment (CGRA), which includes cancer genetic counseling and genetic testing. A Tailored Counseling and Navigation (TCN) intervention successfully increased CGRA uptake among women with a history of cancer who enrolled in a randomized controlled trial. Understanding reasons for TCN’s effectiveness can guide future interventions that use risk messages and behavior change techniques. We conducted mediation analyses, which enabled identification of the TCN’s active components. Eligible breast and ovarian cancer survivors (n = 641) were recruited from three statewide cancer registries and were assigned to three groups: TCN, Targeted Print, and Usual Care. Mediator variables drawn from behavioral and risk communication theories were assessed at baseline and 1-month follow-up; CGRA uptake was assessed at 6 months. The strongest mediator was intention to obtain a CGRA, followed by self-efficacy, perceived risk, knowledge of hereditary breast and ovarian cancer, and perceived CGRA benefits. Risk communication and behavioral change interventions for hereditary cancer should stress a person’s increased genetic risk and the potential benefits of genetic counseling and testing, as well as bolster efficacy beliefs by helping remove CGRA barriers. System-level and policy interventions are needed to further expand access.
Identifiants
pubmed: 37658805
pii: 7258966
doi: 10.1093/abm/kaad048
pmc: PMC10578392
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-977Subventions
Organisme : NCI NIH HHS
ID : 3P30CA072720
Pays : United States
Organisme : ORFDO NIH HHS
ID : 75N99021D00009
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211625
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800014I
Pays : United States
Organisme : CDC HHS
ID : 5NU58DP006279
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00009
Pays : United States
Organisme : NIEHS NIH HHS
ID : 75N96021D00009
Pays : United States
Organisme : CLC NIH HHS
ID : 75N90021D00009
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Informations de copyright
© Society of Behavioral Medicine 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
Am Psychol. 2009 Sep;64(6):527-37
pubmed: 19739882
Behav Cogn Psychother. 2015 Mar;43(2):129-41
pubmed: 24229732
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Cancer Cell Int. 2021 Sep 25;21(1):512
pubmed: 34563200
Health Commun. 2013;28(1):72-83
pubmed: 23330860
Public Health Genomics. 2016;19(1):1-10
pubmed: 26389838
J Gen Intern Med. 2008 May;23(5):561-6
pubmed: 18335281
J Health Commun. 1996 Oct-Dec;1(4):317-41
pubmed: 10947367
Annu Rev Public Health. 2010;31:399-418
pubmed: 20070207
Int J Gynecol Cancer. 2013 Mar;23(3):431-6
pubmed: 23354368
Psychooncology. 2015 Oct;24(10):1265-1278
pubmed: 26194469
JAMA. 2021 Sep 21;326(11):1045-1056
pubmed: 34546296
Psychol Health. 2008;23(3):259-63
pubmed: 25160477
Cancers (Basel). 2021 Feb 23;13(4):
pubmed: 33672149
J Genet Couns. 2011 Dec;20(6):625-38
pubmed: 21691939
J Health Psychol. 2019 Aug;24(9):1221-1232
pubmed: 28810422
Patient Educ Couns. 2022 Jun;105(6):1488-1494
pubmed: 34649750
J Natl Cancer Inst. 2014 Nov 05;106(12):
pubmed: 25376862
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Clin Cancer Res. 2018 Dec 1;24(23):5910-5917
pubmed: 30082473
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
Ann Behav Med. 2017 Oct;51(5):694-706
pubmed: 28236077
Cancer Nurs. 2023 May-Jun 01;46(3):217-232
pubmed: 35283469
BMC Public Health. 2017 May 25;17(1):503
pubmed: 28545429
Med Decis Making. 2020 Jul;40(5):555-581
pubmed: 32659154
JAMA Oncol. 2015 Dec;1(9):1251-60
pubmed: 26426480
BMC Cancer. 2019 Sep 2;19(1):871
pubmed: 31477094
Am J Prev Med. 2014 May;46(5):440-8
pubmed: 24745633
J Clin Oncol. 2023 Mar 20;41(9):1703-1713
pubmed: 36623243
J Clin Oncol. 2016 Aug 1;34(22):2610-8
pubmed: 27161971
Dela J Public Health. 2021 Dec 15;7(5):40-41
pubmed: 35619977
Gynecol Oncol. 2015 Jul;138(1):109-14
pubmed: 25933682
JAMA. 1996 Jun 26;275(24):1885-92
pubmed: 8648868
J Clin Oncol. 2023 May 20;41(15):2767-2778
pubmed: 36787512
ANS Adv Nurs Sci. 2022 Apr-Jun 01;45(2):179-193
pubmed: 35502990
Can Fam Physician. 2010 Aug;56(8):e308-14
pubmed: 20705870
Health Educ Res. 2008 Jun;23(3):454-66
pubmed: 18349033
Contemp Clin Trials. 2018 Oct;73:123-135
pubmed: 30236776
J Genet Couns. 2018 Feb;27(1):177-186
pubmed: 28785836
J Subst Abuse Treat. 2016 Jun;65:36-42
pubmed: 26874558
Health Educ Behav. 2012 Aug;39(4):455-73
pubmed: 22002250
J Cancer Educ. 2023 Feb;38(1):42-49
pubmed: 34523076
J Obstet Gynecol Neonatal Nurs. 2002 Sep-Oct;31(5):570-81
pubmed: 12353737
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Integr Cancer Sci Ther. 2017 Feb;4(1):
pubmed: 28706734